Edition:
United States

Profile: INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

8.97USD
20 Sep 2017
Change (% chg)

$-0.04 (-0.44%)
Prev Close
$9.01
Open
$8.96
Day's High
$9.05
Day's Low
$8.92
Volume
25,963
Avg. Vol
168,322
52-wk High
$15.01
52-wk Low
$8.70

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Company Address

INSYS Therapeutics Inc

10220 S 51st St Ste 2
PHOENIX   AZ   85044-5231
P: +1602.9102617
F: +1302.6365454

Company Web Links